XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Segment Reporting                  
Number of operating segments | segment             1    
Grant income             $ 13,407 $ 16,516  
Less:                  
Clinical programs             16,486 22,312  
R&D Personnel costs             6,221 7,520  
Preclinical programs             262 784  
Manufacturing             1,901 1,926  
Other research and development expenses             222 176  
General and administrative expenses (excluding equity-based compensation)             7,307 7,311  
Equity-based compensation $ 522     $ 896     1,729 3,214  
Other segment items             (577) (598)  
Net loss $ (4,930) $ (6,734) $ (8,480) $ (9,937) $ (7,041) $ (9,151) $ (20,144) $ (26,129) $ (33,971)
Other segment reporting description             Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary